New insider Malzahn Craig claimed ownership of 17,819 shares (SEC Form 3)
$RGNX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/13/2025 |
3. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 17,819(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Options (Right to buy) | (2) | 12/02/2029 | Common Stock | 31,200 | $40.68 | D | |
| Stock Options (Right to buy) | (2) | 01/04/2031 | Common Stock | 9,600 | $44.97 | D | |
| Stock Options (Right to buy) | (3) | 01/03/2032 | Common Stock | 9,600 | $34.31 | D | |
| Stock Options (Right to buy) | (4) | 01/03/2033 | Common Stock | 19,130 | $22.25 | D | |
| Stock Options (Right to buy) | (5) | 01/02/2034 | Common Stock | 12,750 | $18.34 | D | |
| Stock Options (Right to buy) | (6) | 01/02/2035 | Common Stock | 33,150 | $7.86 | D | |
| Explanation of Responses: |
| 1. Includes 9,988 shares of common stock underlying time-based restricted stock units. |
| 2. As of the date of this report these options are fully vested and exercisable. |
| 3. 25% of the shares vested on January 3, 2023. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. |
| 4. 25% of the shares subject to this option vested on January 3, 2024. The balance will vest in equal monthly installments over the 36 months following January 3, 2024 while the optionee provides continuous service to the Issuer. |
| 5. 25% of the shares subject to this option vested on January 3, 2025. The balance will vest in equal monthly installments over the 36 months following January 3, 2025 while the optionee provides continuous service to the Issuer. |
| 6. 25% of the shares subject to this option shall vest on January 3, 2026. The balance will vest in equal monthly installments over the 36 months following January 3, 2026 while the optionee provides continuous service to the Issuer. |
| Remarks: |
| EXHIBIT LIST - Exhibit 24 - Power of Attorney for Craig Malzahn |
| /s/ Patrick J. Christmas as attorney-in-fact | 03/24/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||